No headlines found.
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
PRNewswire (Wed, 3-Apr 2:33 PM ET)
Ampio Announces Voluntary Delisting and SEC Deregistration
PRNewswire (Mon, 25-Mar 5:00 PM ET)
Ampio Provides Update on Results from Pre-IND Enabling Studies
PRNewswire (Wed, 14-Feb 5:45 PM ET)
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development of a potential treatment for osteoarthritis of the knee ("OAK") as part of its OA-201 development program ("OA-201 program" or "OA-201").
Ampio Pharmaceuticals trades on the stock market under the symbol AMPE.
As of April 24, 2024, AMPE stock price was flat at $0.62 with million shares trading.
AMPE has a beta of 1.58, meaning it tends to be more sensitive to market movements. AMPE has a correlation of 0.03 to the broad based SPY ETF.
AMPE has a market cap of $703,922.00. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that AMPE belongs to (by Net Assets): VXF.
AMPE has underperformed the market in the last year with a price return of -84.8% while the SPY ETF gained +24.1%. AMPE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -61.7% and -27.1%, respectively, while the SPY returned +4.5% and -1.7%, respectively.
AMPE support price is $.57 and resistance is $.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMPE stock will trade within this expected range on the day.